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Abstract  
The enzyme poly(ADP-ribose) glycohydrolase (PARG) performs a critical role in the repair of DNA 
single strand breaks (SSBs). However, a detailed understanding of its mechanism of action has been 
hampered by a lack of credible, cell-active chemical probes. Herein, we demonstrate inhibition of 
PARG with a small molecule, leading to poly(ADP-ribose) PAR chain persistence in intact cells. 
Moreover, we describe two advanced, and chemically distinct, cell-active tool compounds with 
convincing on-target pharmacology and selectivity. Using one of these tool compounds we 
demonstrate pharmacology consistent with PARG inhibition. Further, while the roles of PARG and 
poly(ADP-ribose) polymerase (PARP) are closely intertwined, we demonstrate that the pharmacology 
of a PARG inhibitor differs from that observed with the more thoroughly studied PARP inhibitor 
olaparib. We believe that these tools will facilitate the wider understanding of this important 
component of DNA repair and may enable the development of novel therapeutic agents exploiting the 
critical dependence of tumours on the DNA damage response (DDR). 
Introduction 
It is estimated that the average cell receives 10,000 DNA damaging events every day.1 In a cancer 
cell, where cellular stress levels are considerably higher and genomic instability rife, it is likely that 
this rate of DNA damage is significantly enhanced. Additionally, cancer cells show increased levels 
of replication stress and loss of one or more DDR pathways, leading to a greater dependency on the 
remaining pathways (Reviewed in 2). Given this context, it is unsurprising that inhibition of DNA 
repair is a major focus for cancer biologists. In parallel, the therapeutic opportunities in this area are 
the subject of considerable attention, and several agents targeting key pathways are now in clinical 
evaluation. Whilst agents targeting the ataxia telangiectasia and Rad3-related protein (ATR) and 
ataxia telangiectasia mutated (ATM) kinases involved in DNA double strand break (DSB) repair are 
currently undergoing clinical evaluation,3-5 considerably more effort has been directed towards 
developing inhibitors of the enzyme poly(ADP-ribose) polymerase (PARP), shown to be synthetic 
Page 3 of 34
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3 
 
lethal in homologous recombination-deficient (HR-deficient) cancers, such as those having lost the 
BRCA 1/2 genes.6 
PARP recognises sites of DNA single strand breaks (SSBs) and acts as a recruitment hub for the 
apparatus required to effect repair of SSBs, such as XRCC1, LIG3 and POLB.7 Upon recognition of 
the SSB, PARP auto-ribosylates to form branched poly(ADP-ribose) (PAR) chains, often containing 
up to 200 ADP-ribose units.8 These act as a cellular marker of DNA damage and facilitate the 
recruitment of repair factors. Inhibition of this process, therefore, leads to replication fork disruption, 
conversion of the SSBs to DNA DSBs and, in the absence of DSB repair, cell death.9 Exploitation of 
this mechanism has led to a plethora of PARP inhibitors entering clinical trials,10 of which olaparib 
(Lynparza™) was the first to gain FDA regulatory approval in 2015.11 However, emergence of 
resistance to PARP inhibitors, possibly through positive selection of rare BRCA2 revertant clones, has 
already been found in patients. Additional mechanisms for resistance that have been identified in 
animal models may yet materialise in the clinic.12 
Also critical to this repair process is the orderly degradation of the PAR chains. Although the exact 
timing and order of events remains unclear, it is evident that the inability to degrade PAR chains has a 
number of important consequences for the cell. First, PARP-dependent DNA SSB repair cannot be 
completed, presumably due to inefficient recruitment of necessary repair factors.13 Second, as the 
active PARP remains PARylated and sequestered at the original site of damage it is unavailable to 
facilitate repair at other sites of damage.14 Third, as ADP-ribose is “locked in” to the PAR chains, 
NAD levels drop after DNA damage,15 perhaps due to NAD recycling impairment, potentially 
impeding both the ability of the cell to effectively control levels of oxidative stress and leading to 
metabolic catastrophy.16 
This vital degradation of nuclear PAR chains is effected by a single enzyme, poly(ADP-ribose) 
glycohydrolase (PARG). Despite the crucial role of this enzyme in the repair of SSBs, a detailed 
knowledge of its mechanism of action remains elusive. Moreover, PARG offers an intriguing point of 
therapeutic intervention in DNA repair. The PARP family of ADP-ribosyl transferases17 comprises 17 
Page 4 of 34
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4 
 
different known genes,18 of which the current PARP inhibitors inhibit PARPs 1–3 to varying 
degrees.19,20 This leads to the possibility of “therapeutic slippage”, where uninhibited isoforms can 
partly compensate for the loss of activity in the inhibited isoforms. In contrast, PARG exists as a 
single gene with a conserved catalytic domain across all isoforms,21  offering a more critical nodal 
point for inhibition.  
 
Early work on inhibition of PARG relied on bovine rather than human PARG protein.22 Furthermore, 
assessment of the putative inhibitors GPI-16552 and gallotannin showed that their effects were either 
non-existent or off-target in cell models.23 Whilst reports of alternate PARG inhibitors sporadically 
appear in the literature,24-26 we were unable to demonstrate robust pharmacology for the two most 
credible reported inhibitors at the outset of our studies, namely the salicylanilides24 and RBPI-3.27 In 
our hands, the most potent salicylanilide inhibited PARG at around 130 µM in our biochemical 
assays. RBPI-3 behaved as an interference compound in our biochemical assay and we were therefore 
unable to obtain robust data with this agent. Of the remaining reported inhibitors, many contain 
structural features common to assay interference compounds (PAINs)28 (Supplementary Note 1) and 
the utility of these agents as chemical tools has been questioned, with strong concerns raised 
regarding the lack of potency, selectivity and drug-likeness of the reported agents.23 We and others 
believe these issues preclude their assessment as therapeutic agents and their utilisation in the 
unravelling of the mechanism of action of PARG.29 To address this shortcoming, we herein describe 
our studies leading to novel, cell-active in vitro chemical probes which offer potent and selective 
inhibition of PARG in the cellular context. Further, we report convincing mechanism of action studies 
to demonstrate on-target pharmacology, which phenocopy those seen with siRNA against PARG.30, 31 
Although PARG inhibition would be expected to reduce PARP DNA binding and enzymatic 
activity32, 33 we show that these novel PARG inhibitors offer overlapping yet distinct pharmacology to 
that observed through inhibition of their PARP counter-proteins. 
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RESULTS AND DISCUSSION 
Identification of PARG inhibitors. 
Our efforts commenced with a hit from an HTRF-based high throughput biochemical screen of 1.4M 
compounds, conducted at AstraZeneca. After orthogonal confirmation of early hit matter at 
AstraZeneca, just three structurally-related hit compounds remained, typified by 1 (Figure1a). This 
anthraquinone sulphonamide showed modest biochemical potency (Figure1b) and, surprisingly, was 
roughly equipotent in an acute (one hour) cellular assay of PAR chain persistence (Figure 1c). We 
believe this to be the first demonstration of PARG inhibition in a whole-cell context. Binding to 
human PARG was confirmed by SPR analysis, which indicated a KD of 1.35 µM and this binding was 
found to exhibit a 1:1 stoichiometry and the compound exhibited fast on/fast off kinetics, with a 
dissociation rate constant (Kd) of 0.34 s
-1 (Figure 1d).  
This success was, however, tempered by the finding that the compound showed cytotoxicity (after 72 
h) at doses comparable to those required for PARG inhibition (Figure 1c). This finding was not 
unexpected, given the flat aromatic structure, which is typical of a DNA-intercalating chemotype (see, 
for example 34). Clearly, a more attractive chemical template for further optimisation was required and 
several options, including iterative chemical modification and optimisation of the existing chemotype, 
were considered. A number of PARG X-ray crystal structures have become available in recent years, 
including complexes with substrate mimetics, which have furthered our understanding of the nature of 
the substrate binding site and PARG’s catalytic mechanism. We determined the X-ray crystal 
structure of 1 bound to the catalytic domain of human PARG (unpublished data). The anthraquinone 
was observed to bind in the ADP-ribose binding site, stacked between the aromatic sidechains of 
Tyr795 and Phe902, in a subsite observed in other crystal structures to be occupied by the adenine 
moiety of ADP-ribose 35 or the RBPI-3 inhibitor.25 
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This knowledge of the PARG crystal structure and its interactions with bound ligands prompted us to 
pursue a focussed virtual screening campaign as a route to identifying novel chemotypes, devoid of 
the undesirable anthraquinone structural feature, that were predicted to form similar interactions in the 
substrate-binding site, specifically the aromatic stacking interactions of the anthraquinone core and 
the network of hydrogen bonds around the sulfonamide moiety. In brief, a search of commercially 
available chemical space for compounds matching a pharmacophore derived from the observed 
binding mode of 1, followed by filtering for drug-like physicochemical properties, yielded a set of 
around 30 000 chemically diverse aryl sulfonamides that were subsequently docked into the crystal 
structure of human PARG. On the basis of the predicted binding modes and the potential for further 
chemical optimisation, a moderate set of around 70 compounds was selected for purchase and 
biochemical screening. From these studies, a number of bicyclic ring systems, including 
quinazolinedione and benzimidazolone scaffolds, were identified as potential replacements for the 
anthraquinone which do not carry a known intercalator liability, albeit with only modest activity at 
this stage.  
Limited, parallel optimisation of the original anthraquinone hit 1 had confirmed the absolute 
requirement for a small alkyl substituent attached to the sulphonamide nitrogen and, from this work, a 
cyclopropylmethyl moiety emerged as a preferred substituent (unpublished data). Combining this 
moiety with the novel quinazolinedione scaffold led to 2 (Scheme 1), which was of modest and 
roughly equal potency in both our biochemical and cell assays. Further structure-guided design and 
medicinal chemistry optimization led to the elaborated bis-cyclopropyl derivative 3 (Scheme 1), 
which showed excellent potency in our cell assay system. Moreover, the co-crystal structure of this 
compound bound to human PARG was successfully obtained at a resolution of 2.23 Å (Figure 2a), 
further demonstrating the selective engagement of this compound with the active site of PARG. The 
PARG-3 complex crystal structure recapitulated the key interactions identified in the binding of 1 to 
human PARG, as well as additional interactions in the vicinity of Phe902 from the quinazolinedione 
nitrogen substituents, which accounted for the improved binding affinity compared with 2. The close 
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agreement between modelled and experimental binding modes increased our confidence that our 
docked models were accurate and could be used to help focus future medicinal chemistry design. 
Throughout the optimisation programme, we observed a strong correlation between the biochemical 
and cell assay data, apart from a few compounds likely to have impaired permeability due to inclusion 
of acidic or basic moieties. (Figure 3a). This correlation supported the hypothesis that the observed 
pharmacology was directly related to PARG inhibition in both assay systems.  
The excellent observed potency of 3 was tempered by poor aqueous solubility (< 10 µM in 1% 
DMSO/PBS), limiting its scope as a probe compound. In order to improve in vitro DMPK parameters,  
further optimisation of the quinazolinedione series led to the probe compound 4 (Figure 3b).36 Similar 
structure-guided approaches were pursued in parallel to additionally deliver the elaborated 
benzimidazolone 5.37 These derivatives, showing similar potency to 3 in the biochemical assay 
(Figure 3c) displayed considerably enhanced aqueous solubility (> 100 µM in 1% DMSO/PBS). The 
derivatives were almost equipotent in cellular assays (Figures 3d and 3e) and were able to maintain 
PAR chains for at least 5 hours after dosing (Supplementary Figure 1). The docked model of 4 bound 
to human PARG is shown in Figure 2b, and indicates that 4 shows a similar binding mode to 3, with 
the quinazolinedione substituents forming a bidentate “pincer” interaction around Phe902, 
rationalising the high potency observed in this series of compounds. The outline progression of this 
template to deliver 4 is described in Scheme 1 and, whilst the specific details of this process are 
outside the scope of this particular communication, a detailed description of the discovery and 
medicinal chemistry optimisation of this chemotype will be fully disclosed elsewhere in due course.  
In addition to the routine biochemical and cellular assay evaluation described above, these tool 
compounds were shown to be devoid of activity against both PARP1 and ARH3, the closest known 
functional homologue to PARG (Supplementary Figure 2 and see also 21). Furthermore, we were also 
able to demonstrate that the closely related analogue compounds 6 and 7 (Figure 3b) were inactive 
against PARG in the biochemical assay (IC50 > 100 µM, Supplementary Figure 3). Simple 
methylation of the sulphonamide moiety was found to disrupt PARG-binding interactions, rendering 
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these compounds inactive (Figure 3d) and providing useful controls to demonstrate on-target 
pharmacology of the active probe compounds.  
To further confirm binding of these tool compounds to human PARG, 4 and 5 were subjected to 
analysis by SPR (Figure 3f and 3g). Pleasingly, both compounds demonstrated stoichiometric binding 
to the protein and, consistent with their improved biochemical potency, both derivatives showed 
considerable improvements in KD compared to the original hit 1 (1.45 nM and 3.09 nM for 4 and 5, 
respectively).  Moreover, the binding kinetics of these derivatives indicated an increased on rate, 
alongside considerable elongation of dissociation kinetics, with Kd of 0.007 and 0.023 s
-1 for 4 and 5. 
This longer off-rate suggests much tighter binding of these ligands to human PARG, potentially due 
to the increased interactions of the “pincer” arrangement around Phe902, described above. 
Unlike our experiences with 1, in the absence of extrinsic DNA damaging agents, both 4 and 5 
displayed considerably less cytotoxicity at 72 h relative to their cellular PARG IC50s (Figure 3h and 
Table 1). However, the benzimidazolone derivative 5 did display modest cytotoxicity, albeit at doses 
some 350-fold above the doses required for PARG inhibition, whereas the quinazolinedione 4 
appeared to be devoid of any such off-target activity. Furthermore, the compounds with no 
measureable PARG activity confirmed that compounds bearing the quinazolinedione scaffold (4 and 
6) were non-cytotoxic, whilst the benzimidazolone-derived compounds (5 and 7) had modest inherent 
toxicity associated with the template. Given this finding, the quinazolinedione scaffold became our 
preferred tool compound chemotype and, as such, further studies were performed exclusively with 4. 
In vitro DMPK profiling of 4 demonstrated that the compound did not inhibit a suite of the five 
common Cytochrome P450 enzymes at 10 µM, delivered good aqueous solubility (>100 µM, 1% 
dimethyl sulfoxide (DMSO) in phosphate buffered saline (PBS), pH 7.4) and a measured LogD of 
2.86 at pH 7.4. Moreover, profiling against a panel of common safety-related ion channels, enzymes 
and receptors showed no significant binding against any target at 10 µM, further demonstrating the 
selective pharmacology of this agent (Supplementary Table 1). However, the compound was found to 
suffer from relatively rapid clearance when incubated with both mouse and human microsomes 
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(Intrinsic clearance (CLint) 211 and 78 µL min
-1 mg-1, respectively). Whilst these data do not limit the 
use of the compound to elucidate the in vitro pharmacology of PARG inhibition, we would urge 
caution in the use of this agent for in vivo studies, due to the anticipated low exposures commensurate 
with these clearance values. 
Mechanism of action studies. 
PARG is known to play an intimate role in SSB repair, hydrolysing the PAR chains built up by 
PARP(s). A functional reduction of PARG would therefore be expected to lead, at least initially, to 
unrepaired SSBs, which upon collision with a replication fork result in one-ended DSBs.38 Knockout 
of PARG in embryonic stem cells showed an increase in double strand breaks detected by 
phosphorylated H2AX (γH2AX 39). We therefore investigated whether this effect was recapitulated by 
small molecule inhibition of PARG. MCF-7 cells treated with a low dose (5 µg mL-1) of the DNA 
damaging agent methylmethane sulfonate (MMS) suffered only a modest decrease in cell number 
over 24 h (Supplementary Figure 4). The total intensity of γH2AX staining after 24 h of exposure to 
MMS alone was only barely detectable (Supplementary Figure 5c). Likewise, treatment with the 
PARG inhibitor 4 at doses up to 30 µM only modestly increased γH2AX intensity above background 
levels (Supplementary Figure 5a,b). However, combination of DNA damage and PARG inhibitor 4 
increased the intensity of γH2AX in a dose-dependent manner (Figure 4a, Supplementary Figure 6). 
In contrast, the combination of MMS with the biochemically inactive analogues (6 or 7) had no 
substantial effect on γH2AX intensity. The PARP inhibitor olaparib has only a moderate effect on 
proliferation in MCF-7 cells (40 and Supplementary Figure 7) and only modestly increased γH2AX 
intensity in combination with MMS at the highest dose (30 µM, Figure 4a). This suggested that 
PARG inhibition has a different downstream consequence on DNA repair compared with PARP 
inhibition by olaparib. PARylated PARP1 has a high affinity for non-nucleosomal histones and 
varying the amount of PARP modification can switch the affinity of PARP between histones and 
native chromatin in in vitro assays.41 However, it is currently unclear whether maintaining 
PARylation of PARP in cells via PARG inhibition leads to PARP remaining bound to DNA and 
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incomplete DNA repair or if PARG inhibition leads instead to a pool of PARylated PARP that is 
unable to be recycled to new single-strand breaks. Regardless of the exact mechanism, depletion of 
PARG has been shown to lead to increased levels of γH2AX in murine and human cells.39, 42 
Inhibition of PARG with 4 consolidates these previous results. Our experiments were conducted over 
24 h and therefore only designed to study the disruption of DNA repair by inhibiting PARG. Notably, 
in the absence of MMS, PARG inhibition does not increase γH2AX in HeLa cells, suggesting that in 
some tumor cell lines redundant mechanisms may be able to repair DNA sufficiently for cell 
proliferation to progress. 
 
PARP utilizes NAD as the substrate to create chains of PAR primarily on PARP1, and this has been 
shown to lead to a temporary drop in NAD levels after alkylating DNA damage, resulting in transient 
cellular NAD concentrations of just a fifth of normal levels in some instances.15,43 Under normal 
circumstances, PARG subsequently releases monomers of ADP-ribose from PAR which are then 
thought to be recycled to NAD using NAD salvage pathways and the involvement of Nicotinamide 
phosphoribosyltransferase (NAMPT).44 We speculated that by inhibiting PARG we may exacerbate 
the fall in NAD seen after DNA damage and indeed, treatment of HeLa cells with MMS led to a dose-
dependent decrease in NAD/H levels that could be moderately enhanced with the NAMPT inhibitor 
FK866 (Figure 4c, d). PARP inhibition using olaparib diminished the acute effect on NAD/H 
although this did not protect cells from cell death at later time points (Supplementary Figure 8). In 
contrast, PARG inhibition using 4 greatly enhanced NAD/H depletion beyond that of MMS alone 
(Figure 4c, d). In addition, the inactive analogue 6 had no effect on NAD/H depletion induced by 
MMS. This further provided evidence to support the hypothesis that PARG inhibition is functionally 
differentiated from PARP inhibition by olaparib. NAD is an important cofactor utilized heavily in 
those tumor cells that primarily deploy NAD salvage pathways in preference over de-novo synthesis 
and this pathway reliance therefore offers an attractive target for therapeutic intervention.45 After 
DNA damage and subsequent PARG-mediated hydrolysis, ADP-ribose is normally transformed into 
ribose-5-phosphate by ADP-ribose pyrophosphatase and subsequently fed into the NAD salvage 
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pathway.44 These findings suggest that inhibition of PAR chain hydrolysis could limit this critical 
replenishment of NAD. As such, depletion of NAD as a consequence of PARG inhibition may 
provide a route to tumor/host selectivity as has recently been described in the application of NAMPT 
inhibitors with tumors harboring mutant IDH1.46 
 
PARP inhibitors are proposed to play dual roles in cells acting as sensitizers to DNA damaging 
agents/radiotherapy and/or demonstrating efficacy in a synthetic lethality setting.47 Targeting DNA 
repair pathways in this manner appears to require longer target-inhibitor engagement times, and it was 
only after long-term clonogenic assays that the synthetic lethality with BRCA genes and olaparib 
became apparent. As PARG inhibitors were initially predicted to be active in the same clinical 
population as for PARP (i.e. BRCA1/2 mutant) and knockdown of PARG and BRCA2 reduced cell 
viability in a breast cancer cell line17, we carried out preliminary clonogenicity assays with a small 
number of breast cancer cell lines. However, our initial data indicated that cell lines containing 
mutations in BRCA1 or BRCA2 were not exquisitely sensitive to PARG inhibitors. We therefore 
explored this further using additional clonogenicity assays on a selected panel of breast cancer cell 
lines with differing genetic backgrounds (Figure 5a). MDA-MB-436 cells carry the 5396 + 1G>A 
mutation in BRCA1 and are known to be sensitive to PARP inhibition48 and this was confirmed in our 
studies where the IC50 for olaparib was <0.1 µM. In contrast, in this cell line the PARG inhibitor 4 
was less active (IC50 0.8 µM). HCC1937 cells carrying the 5382insC mutation in BRCA1 are 
relatively resistant (>10 µM) to olaparib in our hands (in agreement with 48), and likewise the PARG 
inhibitor had little effect on these cells. However, ZR-75-1 cells that are BRCA1 and BRCA2 wild type 
were found to be exquisitely sensitive to PARG inhibition by 4 (0.2 µM). In these cells, olaparib 
showed a modest effect, but was less potent than the PARG inhibitor. Thus, while olaparib resistant 
HCC1937 cells are also resistant to PARG inhibition, and olaparib sensitive MDA-MB-436 cells are sensitive to 
PARG inhibitors, PARP inhibitor sensitive cells of differing genetic backgrounds have differing relative 
responses to PARG inhibition. Therefore the downstream consequences following inhibition of PARG or PARP 
may differ in different genetic backgrounds. This suggests that as well as sharing target populations with PARP 
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inhibitors, there may be additional clinical populations that could respond to PARG inhibitors better than to 
PARP inhibitors.  
It is now accepted that PARP inhibitors induce lethality as a consequence of their trapping of PARP1 
on DNA breaks rather than PARP inhibition per se49-51. It is therefore plausible that PARG inhibition 
may not replicate the PARP “poisoning” seen with various PARP inhibitors. We therefore 
investigated whether the differential sensitivity to PARG inhibitors was a consequence of a 
differential expression of PARP or PARG protein or due to differing basal PAR levels (supplementary 
figure 9). However there was no clear correlation between these levels and sensitivity to PARG 
inhibition. Efforts to understand the drivers and genetic backgrounds responsible for this sensitivity 
are currently underway and we anticipate that this understanding will help in defining initial clinical 
hypotheses for the application of PARG inhibitors in a therapeutic setting. 
 
Conclusions. 
We have discovered a novel, cell-active PARG inhibitor and have used this to perform initial 
investigations into PARG pharmacology. The provision of a closely related but inactive partner 
compound, and a chemical probe from a different chemical series, increases confidence that the 
observed activity is on target and related directly to inhibition of PARG enzymatic activity. The active 
conjoiner 4 has been used to demonstrate PAR chain persistence in both biochemical and cellular 
contexts and demonstrate that, when cells are challenged with a DNA damaging agent, this inhibition 
leads to DNA DSBs and reduction of colony forming potential in sensitive cell lines. Furthermore, 
these agents do not display acute toxicity or SSB to DSB progression in cells where this challenge 
with DNA damaging agents is absent, indicating that the clinical application of PARG inhibitors may 
provide a well-tolerated point of intervention in the DNA damage repair pathways of tumors. 
Moreover, our preliminary studies indicate that, whilst the enzymes operate at complementary points 
on the same repair pathway, inhibition of PARP and PARG delivers differing phenotypes and 
sensitivities in different cellular and genetic backgrounds. These data suggest that PARG inhibitors 
will be differentiated from the well-known PARP inhibitor olaparib though the full extent and 
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implications of this differentiation are unclear at this early stage. We suggest that these tools will 
facilitate a deeper understanding of the role of PARG, both in DNA repair and in many other, hitherto 
hypothetical, biological processes. 
METHODS 
Chemical synthesis. Compounds were prepared as outlined in Schemes 2 and 3, and as fully 
described in the Supporting Information. For some graphs in this manuscript values are given as pIC50 
which is the negative log of the molar IC50 value.  
PARG Biochemical Assay.This assay was conducted according to the published protocol.21 Briefly, 
PARG in vitro assays were conducted in a total volume of 15 µl in a standard 384-well format. 5 µl of 
human full length PARG (AstraZeneca),35 used at a final reaction concentration of 65 pM, was added 
to 5 µL of Bt-NAD ribosylated PARP1 substrate (AstraZeneca) at a final reaction concentration of 4.8 
nM in assay buffer (50 mM Tris pH 7.4, 0.1 mg mL-1 BSA, 3 mM EDTA, 0.4 mM EGTA, 1 mM 
DTT, 0.01% Tween 20, 50 mM KCl). The reaction was incubated at room temperature for 10 min and 
then 5 µL detection reagent was added. Detection reagent consists of 42 nM MAb anti-6HIS XL665 
(CisBio: 61HISXLB) and 2.25 nM streptavidin europium cryptate (CisBio: 610SAKLB), both at 3× 
working stock concentrations (final concentrations of 14 nM and 0.75 nM respectively), in detection 
buffer (50 mM Tris pH 7.4, 0.1 mg mL-1 BSA and 100 mM KF). Following incubation at room 
temperature for 60 min in the dark, TR-FRET signal was measured at λEx 340 nm and λEm 665 nm 
and λEm 620 nm using a PHERAstar FS plate reader (BMG Labtech). The ratio was calculated as 
[Em665/EM620]×104 for each well and used to calculate percent inhibition for test compounds. Note 
that in this assay PARP1 has a HIS-tag, allowing binding of an anti-HIS MAb-XL665 acceptor 
molecule, whereas biotinylated PAR on the auto-ribosylated PARP1 binds to a donor molecule, 
streptavidin–europium cryptate.  At sites where PARG has hydrolyzed the O-glycosidic bonds within 
the PAR chains there is reduced biotinylated PAR available to bind to the streptavidin, thus resulting 
in a loss of FRET signal. 
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ARH3 Biochemical Assay.ARH3 in vitro selectivity assays were conducted in a total volume of 15 
µL in a standard 384 well format. 5 µL of human full length ARH3 (Enzo Life Sciences: ALX-201-
292), used at a final reaction concentration of 20 nM, was added to 5 µL of Bt-NAD Ribosylated 
PARP1 substrate (Astra Zeneca)35 at a final reaction concentration of 4.8 nM in assay buffer (50 mM 
Tris pH 7.4, 0.1 mg mL-1 BSA, 3 mM EDTA, 0.4 mM EGTA, 1 mM DTT, 0.01% Tween 20, 50 mM 
KCl).  The reaction was incubated at room temperature for 30 min and then 5 µL detection reagent 
was added. Detection reagent consists of 42 nM MAb anti-6HIS XL665 (CisBio: 61HISXLB) and 
2.25 nM streptavidin europium cryptate (CisBio: 610SAKLB), both at 3× working stock 
concentrations (final concentrations of 14 nM and 0.75 nM respectively), in a detection buffer (50 
mM Tris pH7.4, 0.1 mg mL-1 BSAand 100 mM KF). Following incubation at room temperature for 
60 min in the dark, TR-FRET signal was measured at λEx 340 nm and λEm 665 nm and λEm 620 nm 
using the PHERAstar FS plate reader (BMG Labtech). A ratio was calculated as [Em665/EM620]×104 
for each well and used to calculate percent inhibition for test compounds. Note that in this assay 
PARP1 has a HIS-tag, allowing binding of an anti-HIS MAb-XL665 acceptor molecule, whereas 
biotinylated PAR on the auto-ribosylated PARP1 binds to a donor molecule, streptavidin–europium 
cryptate.  At sites where PARG has hydrolyzed the O-glycosidic bonds within the PAR chains there is 
reduced biotinylated PAR available to bind to the streptavidin, thus resulting in a loss of FRET signal. 
 
 
PARP1 Biochemical Assay. PARP1 in vitro selectivity assays were conducted in a 10 µL reaction 
volume in a NUNC maxisorp 384-well assay plate pre-coated in-house with histones. (Briefly, 100 µl 
well−1 of a 1: 1 mixture of Histone H1 [Merck Millipore, 14-155] and Histone type IIa [Sigma, 
H9250] at 0.0625 mg ml−1 in 100 mM sodium carbonate buffer (pH 9.5) was added to the plate and 
incubated overnight at 4 °C before washing three times with 100 µl per well with PBS/0.1% Triton 
X100.)  5 µL of human high specific activity PARP1 (Trevigen: 4668-100-01) was used at a final 
reaction concentration of 0.02 units mL-1 in 1× PARP buffer (Trevigen: 4671-096-02) with 5 µL of 
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1X PARP cocktail, which is a mixture of 10× PARP cocktail (Trevigen: 4671-096-03), 10× activated 
DNA (Trevigen: 4671-096-06) and 20× PARP buffer (as above). The reaction was incubated at room 
temperature for 60 min to allow histones on the coated plate to become PARylated. The wells were 
washed with PBS/0.1% Triton X100 and PARP1 activity was then detected by measuring the extent 
of PARylation. Firstly, 10 µL of streptavidin-HRP (Trevigen: 4800-30-06), diluted 1 in 250 in 1× 
PARG assay buffer (Trevigen: 4680-096-02), was added to each well and incubated at room 
temperature for 60 min. Secondly, following another wash with PBS/0.1% Triton X100, peroxy glow 
reagents A and B (Trevigen: 4675-096-01 and 4675-096-02) were mixed in equal quantities 
immediately before use and 100 µL was added to each well. Luminescence signal was then measured 
immediately using the PHERAstar FS plate reader (BMG Labtech). 
 
Cell culture. HeLa cells were maintained in RPMI 1640 (Sigma R0883) + 1% Glutamax + 10% FBS, 
ZR-75-1 and HCC1937 were cultured in RPMI 1640, + 1% Na Pyruvate, + 1% L-Glutamine, + 12.5 
mL D-Glucose, + 1% HEPES, + 10% FBS. MDA-MB-436 cells were cultured in RPMI 1640 (Gibco 
42401-018), +1% Glutamax, + 10% FBS, with the addition of 10 ng mL-1 insulin. MCF-7 cells were 
cultured in EMEM+ 1% Na Pyruvate, + 1% L-Glutamine, + 1% Non-essential amino acids + 10% 
FBS. Unless otherwise stated all reagents were purchased from Sigma-Aldrich. All cell lines were 
purchased from ATCC (LGC) and regularly checked for mycoplasma and cell authentication. All 
cells were maintained at sub-confluence at 37 °C in a humidified incubator containing 5% CO2. All 
cell data are the result of at least three independent experiments with three replicates per data point 
unless otherwise stated. 
 
Cellular PAR chain persistence assay. This assay was carried out according to the published 
protocol.52  Briefly, HeLa cells were seeded into 384-well plates and 16–24 h later, were treated with 
inhibitors (10pt dose response, 0.001–30 µM in duplicate) or vehicle (DMSO) control. After 1 h cells 
were co-dosed with MMS at 50 µg mL-1 (final) and incubated for 1 hour at 37°C. Cells were fixed 
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with ice-cold 95% methanol/ phosphate buffered saline (PBS) for 15 min at -20°C and then washed 
once with PBS at room temperature. Cells were then permeabilized using PBS/Triton 0.1% for 20 
min, and washed once in PBS before incubating with anti-PAR antibody (10H, Merck-Millipore) 
overnight at 4°C. Cells were then incubated with anti-mouse Alexafluor 488-conjugated secondary 
antibody (A11029, ThermoFisher) at 1:1000 and Hoechst 33342 (1:5000) and images were captured 
on a CellInsight (ThermoFisher Scientific) and analysed using proprietary software. The mean of the 
intensity of nuclear spots at 488 nM was reported with 25 fields captured from duplicate wells and 
approximately 1100 cells analysed per well. To assess kinetics of PAR chain maintenance Hela cells 
were plated in a 384-well plate and the following day treated with 5 µM PARG inhibitors 4 and 5 for 
1 h. MMS at 50 µg mL-1 (final) was added and incubated for different times. Cells were then fixed 
and processed as above. 
Cytotoxicity assessment. HeLa cells were seeded in 30 µL media at 1×104 cells mL-1 in Greiner 
(#781091) 384-well plates. 16–24 h later, cells were treated with inhibitors (8 pt dose response, 0.01–
30 µM, triplicates) or vehicle (DMSO) control. The outer wells were left un-dosed to account for edge 
effects. After 72 h, 50 µL of 3.7% Formaldehyde/PBS was added to each well and cells were fixed for 
20 min. Cells were then rinsed twice with PBS and stained for 1 h with Hoechst 33342/PBS (1:2000) 
in the dark. After two further rinses with PBS, images were captured and nuclei counted on a 
CellInsight (ThermoFisher). The maximum number of fields (25) were captured from each triplicate 
well which approximated to at least 1000 nuclei in vehicle-dosed wells. 
Surface Plasmon Resonance. Surface Plasmon Resonance (SPR) studies were performed using a 
Biacore 3000 instrument (GE Healthcare).  Briefly, the catalytic domain of human PARG protein was 
immobilised via standard NHS/EDC amine coupling on a Xantec CMD 500m sensor chip to a level of 
4000 response units (RU).  Coupling buffer was 20 mM MES, pH 6.0 in a running buffer of 50 mM 
HEPES, pH 7.0.  Samples were analysed in a running buffer of 20 mM HEPES pH 7.0, 150 mM 
NaCl, 2 mM DTT, 0.001% Tween 20 + 5% DMSO.  Concentration ranges of test compounds were 
optimised according to observed binding kinetics:  Compound 1 between 10-0.156 µM or Compounds 
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4 and 5 between 50-0.78 nM by doubling dilutions in running buffer.  Data shown is from n=1 
performed from a single immobilisation. Kinetic data analysis was performed using Scrubber 2 
software (Version 2.0c 2008, BioLogic Software) based on a fit assuming a 1:1 Langmuir binding 
model with mass transport parameters included.  Two independent experiments were carried out with 
duplicate points.  
NAD assay. HeLa cells were seeded in 30 µL media at 2×104 cells mL-1 in BD Falcon (#353963) 
384-well plates. 16–24 h later, cells were treated with inhibitors (1 µM) or vehicle (DMSO) control. 
After 1 h cells were co-dosed with MMS (10 pt dose response, duplicates) and incubated for 1 hour at 
37 °C in a cell culture incubator. At that point, cells were place on the bench for 5 min and then 30 µL 
of NAD/H-Glo reagent (Promega), prepared according to the manufacturer’s recommendation, was 
added to each well. The cells were incubated for a further 30 min at room temperature and then the 
luminescence was read using a Pherastar plate reader (BMG).  
γH2AX assay. MCF-7 cells were seeded in 30 µL media at 4×104 cells mL-1 in Greiner (#781091) 
384-well plates. 16–24 h later, cells were treated with inhibitors (8 pt dose response, 0.01–30 µM) or 
vehicle (DMSO) control. After 1 h cells were co-dosed with MMS at 5 µg/mL (final) or vehicle 
(DMSO) and incubated for 24 hours at 37°C in a cell culture incubator. Cell staining was carried out 
as for the PAR chain persistence assay but using anti-γH2AX antibody (Millipore 05-636) at 1:2000. 
Image capture and analysis was carried out on the CellInsight (ThermoFisher) with 25 fields captured 
from triplicate wells and a minimum of 600 cells analysed per well. For high quality images of 
γH2AX staining, MCF-7 cells were plated on a 96-well glass-bottomed plate (#164588, 
ThermoFisher) and treated as above. Images were then captured using a 42× water immersion 
objective lens on an Opera Phenix (PerkinElmer). 
Clonogenicity assay. ZR-75-1, MDA-MB-436, HCC1937 cells were seeded at 1000 cells well-1, 600 
cells well-1, and 500 cells well-1 in CytoOne 6-well dishes (STARLAB) in 3 mL of media. The inner 
reservoir of each plate was filled with 10 mL of sterile water. After 16−24 h, cells were dosed with 
olaparib or PARG inhibitor 2 at 0, 0.1, 0.3, 1, 3 and 10 µM and incubated until colonies reached at 
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least 50 cells in size (7−21 days). The media was removed and cells were then fixed with crystal 
violet solution (15 min) and the wells rinsed thoroughly and left to dry. Colonies were counted either 
manually (MDA-MB-436) or using a Gel Count (Oxford Optronix). Colony number was calculated as 
% control (i.e. (colonies in dose x/colonies at DMSO) × 100). Curves were calculated using Prism 
(Graphpad Software Inc) setting DMSO control to a dose of 0.0001 µM. 
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Figures and Legends 
 
Figure 1. Confirmation of PARG activity by initial HTS hit. (a) Chemical structure of 
anthraquinone hit PDD00013907 (1) identified from HTS screen. (b) Activity of 1 in HTRF 
biochemical assay detailed in 21 showing partial inhibition at 100 µM. Data points are shown ± s.e.m. 
(c) Cellular activity and cytotoxicity of (1) in HeLa cells. Intensity of nuclear PAR chain signal 
increases in a dose-dependent manner only in the presence of both PARG inhibitor and 1 h treatment 
with 50 µg mL-1 MMS (green line). After 72 h of treatment with PARG inhibitor 1 cell number is 
decreased (Hoechst-stained nuclear objects – purple line). Data points are shown ± s.e.m. (d) 
Characterisation of the binding kinetics of 1, determined by surface plasmon resonance. Kinetic data 
analysis was performed using Scrubber 2 software. Coloured lines display dose-dependent 
sensorgram responses across a concentration range from 10–0.156 µM. Orange lines correspond to 
curve fitting assuming a 1:1 Langmuir binding model with mass transport parameters included and 
kinetic parameters are listed in the table below the sensorgram. 
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Figure 2. Structural biology and docking. (a) Crystal structure of 3 bound to the catalytic domain of 
human PARG (PDB entry 5LHB). (b) Detail of the highly solvent-exposed binding site of 3. Solvent-
accessible surface coloured by electrostatic potential. (c) Docked model of 4 bound to the crystal 
structure of human PARG (derived from 5LHB), highlighting greater engagement with the shelf 
adjacent to Phe902.  Hydrogen atoms modelled within Maestro, protein-ligand docking performed 
within Glide, and figures prepared within PyMOL (Schrödinger LLC). 
a 
Tyr795 
Phe902 
Glu727 
b 
Tyr795a 
Phe902Y795 
ShelfF902 
Phosphoribose  
siteE727 
c 
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Figure 3. Identification of novel specific cell-active inhibitors of human PARG. (a) Plot of biochemical and cellular pIC50 values for > 600 compounds across both 
templates described in this manuscript. Quinazolinediones are represented as blue dots, benzimidazolones as orange dots.  The solid black line represents a line of 1:1 
correlation with the red dashed lines +/- 0.5 log units, indicating a generally uniform correlation between the two assays. Outliers in the bottom right quadrant generally 
contained motifs known to hinder cell permeability.  (b) Chemical structures and activity of PARG in vitro chemical tools PDD00017273 4, PDD00017238 5 and structures 
of closely related inactive conjoiners 6 and 7. The quinazolinedione and benzimidazolone core motifs of 4 and 5 respectively, are emboldened for reference. (c) Determination 
of biochemical IC50 of 4 and 5 against huPARG showing IC50 of 26 nM and 40 nM respectively. Data points are shown ± s.e.m. (d) 4 and 5, but not 6, 7 or olaparib, maintain 
nuclear PAR chains in cells in a dose-dependent manner after alkylating DNA damage. Data points are shown ± s.e.m.(e) Immunofluorescence of cellular PAR chains after 
treatment with a PARG inhibitor.  Only the combination of 4 with DNA damage displays maintenance of nuclear PAR chains shown in green. (f) Characterisation of the 
binding kinetics of 4, determined by surface plasmon resonance.  Kinetic data analysis was performed using Scrubber 2 software.  Black lines display dose-dependent 
sensorgram responses across a concentration range from 50 − 0.78 nM.  Orange lines correspond to curve fitting assuming a 1:1 Langmuir binding model with mass transport 
parameters included and kinetic parameters are listed in the table below the sensorgram.  (g) Characterisation of the binding kinetics of 5, determined by surface plasmon 
resonance.  Kinetic data analysis was performed using Scrubber 2 software.  Black lines display dose-dependent sensorgram responses across a concentration range from 50 − 
0.78 nM.  Orange lines correspond to curve fitting assuming a 1:1 Langmuir binding model with mass transport parameters included and kinetic parameters are listed in the 
table below the sensorgram.    (h) HeLa cells treated with compounds 1, 4–7 over 72 h. The quinazolinedione (QZD) core shows no toxic liabilities (> 30 µM) in HeLa cells, 
however the benzimidazalone (BI) core (particularly the PARG-inactive analogue) shows some modest toxicity with similar values to the anthraquinone (AQ). An asterisk 
denotes that IC50 values were greater than 30 µM (QZD) or 20 µM (BI) and error bars show the standard deviation. 
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Figure 4. PARG inhibition increases γH2AX and decreases NAD/H after DNA damage. (a) 
Average intensity of nuclear γH2AX after MMS treatment. 24 h of combined PARG inhibition and 
MMS leads to a dose-dependent increase of γH2AX for active compounds 4 and 5. The combination 
of olaparib and MMS only leads to a modest increase in γH2AX and inactive derivatives 6 and 7 do 
not show any substantial increase. (b) Quantitation of EC50 values from three independent 
experiments. Error bars show the standard deviation. (c) Relative NAD/H values measured by 
Promega Glo assay showing that MMS induced a decrease in NAD/H after 1 h that is enhanced by 
pre-treatment with a PARG inhibitor (2). Olaparib pre-treatment diminished the reduction in NAD/H 
whilst an inactive analogue of the PARG inhibitor (6) had no effect. (d) Quantitation of EC50 values 
from three independent experiments also showing effect of NAMPT inhibitor FK866 on NAD/H. The 
asterisks in (b) and (d) denotes that IC50 values were greater than 30 µM and 250 µg mL
-1 
respectively and error bars show the standard deviation. 
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Figure 5. BRCA1 wild type cells are sensitive to PARG inhibition. (a) Representative clonogenic 
assays from ZR-75-1 cells (BRCA1 wt), MDA-MB-436 and HCC1937 (BRCA1 mutants) treated with 
olaparib or PARG inhibitor 4. (b) EC50 values for compound 4 and olaparib. Quantitation of three or 
more independent experiments showing the standard deviation in parentheses.  
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Scheme 1: Outline progression of initial quinazolinedione hit 2 to advanced lead 3 and, finally, to 
chemical probe 4.  
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Scheme 2: Synthesis of compounds 4 and 6. Reagents and conditions: i) (2-Methyl-1,3-thiazol-5-
yl)methanamine, trimethylamine, DMF, 50 °C, 3 h, 74%; ii) Triphosgene, trimethylamine, THF, RT, 
16h, 96%; iii) Chlorosulphonic acid, 60 °C, 3 h, 84%; iv) 1-Methylcyclopropanamine hydrochloride, 
DIPEA, DCM, THF, RT, 3 h, 30%; v) 5-(Chloromethyl)-1,3-dimethyl-1H-pyrazole, potassium 
carbonate, DMF, microwave, 80 °C, 30 min, 72%; vi) Methyl iodide, potassium carbonate, DMF, RT, 
21 h, 23%. 
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Scheme 3: Synthesis of compounds 5 and 7.  Reagents and conditions: i) Methylcyclopropanamine 
hydrochloride, TEA, DCM, RT, 2 h, 94%; ii) (Dimethyl-1,3-thiazol-5-yl)methanamine, TEA, DMF, 
130 °C, 6 h, 86%; iii) Iron, ammonium chloride, EtOH/H2O, 80 °C, 2 h, 90%; iv) 1,1’-
Carbonyldiimidazole, DMF, reflux, 2 h, 75%; v) 5-bromo-1,2,4-thiadiazole, copper (I) iodide, 
potassium carbonate, trans-N,N'-Dimethylcyclohexane-1,2-diamine, dioxane, reflux, 4 h, 25%; vi) 
Methyl iodide, potassium carbonate, DMF, RT, 16 h, 39%. 
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Tables 
Compound Enzyme (µM) Cell (PAR chain) (µM) Cytotoxicity (µM)  
1 >60 >30 16 (±2) 
4 0.026 (±0.003) 0.037 (±0.01) >30  
5 0.040 (±0.007) 0.055 (±0.013) >20  
6 >60 >30 >30  
7 >60 >30  8.8 (±1) 
 
Table 1. Biochemical and cellular IC50 data for original hit 1, active and specific (4, 5) and inactive 
(6, 7) PARG inhibitors. Values quoted are ± standard deviation from three or more independent 
experiments. 
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